Overview
Portfolio
More
Nexusneurotech
San Francisco, United States
Focus on investing in early-stage neurotechnology and biotech solutions that address neurological and psychiatric disorders.
Portfolio
14+
Employees
5+
Founded
2023
AUM
≈ $126.0M
Investment focus
Stages
No stages listed
Industries
No industries listedGeographic scope
United States
Fund details
Funds
Nexus NeuroTech Fund II
Vintage 2025 • $126.0M
Sources
Nexusneurotech
Focus on investing in early-stage neurotechnology and biotech solutions that address neurological and psychiatric disorders.
Portfolio
14+
Employees
5+
Founded
2023
AUM
≈ $126.0M
Funds
Nexus NeuroTech Fund II · Vintage 2025 • $126.0M
Stages
No stages listed
Industries
No industries listedGeographic scope
United States
Sources
Showing 10 of 10 matched portfolio companies
Ampa provides the Ampa One system, a streamlined and intuitive platform for delivering Transcranial Magnetic Stimulation (TMS) therapy. This solution is designed to be faster and more effective than existing TMS options for treating depression. The company focuses on making advanced neurological treatment more accessible and efficient for clinicians and patients.
Beacon utilizes an EEG neurobiomarker platform powered by machine learning to enhance clinical trial efficiency and optimize treatment strategies for neurological and psychiatric disorders. By providing quantitative assessments of brain activity, the platform enables precise dose selection and patient stratification, improving the likelihood of successful treatment outcomes.
Funding: $29.9M
Rough estimate of the amount of funding raised
Funding: $29.9M
Rough estimate of the amount of funding raised
Cortica provides personalized neurological therapies, including Applied Behavioral Analysis (ABA), speech, and occupational therapy, for children with autism and other developmental differences. The startup offers a coordinated, multidisciplinary approach to care, enabling measurable improvements in communication, social skills, and emotional regulation through evidence-based treatment plans.
Founded 2014
1000+
Approximate amount of employees
Funding: $80.0M
Rough estimate of the amount of funding raised
Funding: $80.0M
Rough estimate of the amount of funding raised
Provides an FDA-authorized tool, EarliPoint™, that analyzes children's looking behavior during social interaction videos to detect early signs of autism. This technology enables clinicians to make objective, data-driven diagnoses, improving early identification and treatment accessibility for children on the autism spectrum.
Funding: $41.0M
Rough estimate of the amount of funding raised
Funding: $41.0M
Rough estimate of the amount of funding raised
Develops a precision optogenetic platform that uses light-sensitive inhibitory G protein-coupled receptor opsins to selectively modulate pathological neural activity in real time. This approach targets specific neurons and pathways to treat severe neurological disorders, such as epilepsy and Parkinson’s disease, while minimizing side effects associated with conventional therapies.
Funding: $6.7M
Rough estimate of the amount of funding raised
Funding: $6.7M
Rough estimate of the amount of funding raised
Neuraworx develops bioelectronic solutions focused on enhancing the brain's natural waste clearance mechanisms. The company's core technology, Intelligent Cerebrovascular Pacing™, targets glymphatic system function to improve cerebral fluid homeostasis. This approach aims to facilitate the clearance of harmful biomolecules associated with declining brain health.
Funding: $610.0K
Rough estimate of the amount of funding raised
Funding: $610.0K
Rough estimate of the amount of funding raised
Nobi is an AI-powered smart lamp that utilizes machine learning algorithms to adapt lighting conditions based on user behavior and environmental factors. This technology enhances home safety by providing automated lighting adjustments that reduce the risk of accidents in low-visibility situations.
Rune Labs develops a software platform that integrates with neuromodulation therapies to collect and analyze real-world data from patients with neurodegenerative diseases, particularly Parkinson's. This technology enables clinicians to access personalized patient data and supports life sciences companies in expediting therapy development through enhanced clinical trial processes.
Funding: $42.2M
Rough estimate of the amount of funding raised
Funding: $42.2M
Rough estimate of the amount of funding raised
This startup develops a non-invasive neurostimulation therapy for sleep apnea. Their therapy delivery system opens the airway, addressing the root cause of sleep apnea and allowing patients to sleep peacefully.
Synapticure offers telehealth services for patients with neurodegenerative diseases, providing access to specialized neurologists and personalized care coordination across all 50 states. The platform addresses the lengthy wait times for appointments and the need for comprehensive support by delivering 24/7 care and resources tailored to conditions like ALS, Parkinson's, and Alzheimer's.
Funding: $46.3M
Rough estimate of the amount of funding raised
Funding: $46.3M
Rough estimate of the amount of funding raised
Showing 4 of 4 unmatched portfolio companies